PEG of NanoString Technologies, Inc.
The PEG ratio is calculated by dividing the P/E ratio by the company's expected earnings growth rate in the next 5 years. Since using just the P/E ratio would make high-growth companies appear overvalued relative to others, the PEG ratio is considered to be a convenient approximation. PEG is a widely employed indicator of a stock's possible true value.
Similar to P/E ratios, a lower PEG means that the stock is undervalued more. It is favored by many over the price/earnings ratio because it also accounts for growth. The PEG ratio of 1 is sometimes said to represent a fair trade-off between the values of cost and the values of growth, indicating that a stock is reasonably valued given the expected growth. A crude analysis suggests that companies with PEG values between 0 and 1 may provide higher returns. A PEG Ratio can also be a negative number if a stock's present income figure is negative, (negative earnings) or if future earnings are expected to drop (negative growth). PEG ratios calculated from negative present earnings are viewed with skepticism as almost meaningless, other than as an indication of high investment risk.
NanoString Technologies, Inc. develops, manufactures, and sells life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include nCounter Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples through the images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer pathways gene expression panels, including pathways, immune profiling, and progression panels, as well as nCounter Vantage 3D, other gene expression, miRNA expression, and cancer copy number variation panels. Further, the company offers nCounter Elements reagents that allow users to design customized assays for gene expression, copy number variation, and gene fusions; Master Kits, which include ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. It markets its systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories, as well as to clinical laboratories and medical centers. NanoString Technologies, Inc. has collaboration with Celgene Corporation; Merck Sharp & Dohme Corp.; Medivation, Inc.; and Astellas Pharma, Inc. The company was founded in 2003 and is headquartered in Seattle, Washington.
- NanoString Technologies, Inc., 530 Fairview Avenue North, Seattle 98109, United States
Companies with PEG similar to NanoString Technologies
|NSTG NanoString Technologies, Inc.||NASDAQ > Health Care > Biotechnology: Biological Products (No Diagnostic Substances)||N/A|